CareDx Appoints New Senior Leaders to Significantly Strengthen Key Areas of Their Business

September 10, 2020

CareDx, Inc. today announced the appointment of new senior leaders to significantly strengthen key areas of the business – Digital Services, Laboratory Operations, Business Development, and Market Access.

CareDx Chairman and CEO, Peter Maag said, “As our business continues to grow rapidly, the operational complexity also increases. These talented individuals will help us expand our digital business across the patient continuum, scale our laboratory operations, evaluate future partnerships and acquisitions, and advance our best in class market access strategy.”

Kashif Rathore, Senior Vice President, Digital Business joins CareDx from Cerner, where he held various senior leadership roles. In addition to his most recent role as Vice President of Interoperability, Kashif served in the consulting and technology lines of Cerner’s businesses. Kashif obtained a master’s degree in executive business administration from the Henry W. Bloch School of Management at the University of Missouri-Kansas City. He also holds a bachelor’s degree in management information systems from the University of Central Oklahoma in Edmond, and a bachelor’s degree from the University of the Punjab, Pakistan.

Ryan Phan, Vice President, Lab Operations joins CareDx from Kaiser Permanente, where he was the Managing Director and Head of Regional Molecular Genetics and Cytogenetics Laboratories. Ryan has led multiple strategic laboratory expansions and developed and implemented clinical testing programs. Ryan received his B.A. from the University of California at Berkeley and his PhD from Columbia University. He completed his post-doctoral training in Cancer Genetics and Immunology at Harvard Medical School.

Sean Grant, Vice President, Strategy and Business Development joins CareDx from Citigroup Global Capital Markets, where he served as a Vice President in the Investment Banking Healthcare Division. At Citigroup, Sean specialized in raising public and private capital and executed a broad range of transactions, including M&A for many of the leading life sciences companies around the world. Sean earned an M.B.A. from the Johns Hopkins Carey School of Business and a B.A. in Government and International Politics from George Mason University.

Danielle Scelfo, Vice President, Market Access and Health Policy joins CareDx from Hologic, where she was the Senior Director of Health Policy and Reimbursement. Danielle brings more than 25 years of health policy and strategic market access experience to CareDx, including roles at Genomic Health and Adaptive Biotechnologies. Danielle holds a master’s in health service administration from Florida International University and a bachelor’s degree in Marketing from the University of Florida.

SourceCareDX

Hot this week

Medtronic Expands AiBLE Spine Surgery Ecosystem with New Technologies and Siemens Healthineers Partnership

New advancements in the AiBLE Spine Surgery ecosystem build upon the company's commitment to procedural innovation and execution

Axlab, Danish Medtech Pioneer, expands to US with Advanced Robotic Tissue Sectioning for Pathology Laboratories

Kris Rokke, National Sales Director for Axlab in the US. "My team and I are extremely excited and honored about this unique opportunity to also offer this advanced technology to labs across the US and thus contribute to the pathology labs of tomorrow."

Spartan Medical Broadens Single-Use Sterile Instrument Portfolio to Improve Outcomes, Increase Efficiency, and Generate Cost Savings

Spartan Medical products portfolio of single-use, sterile med tech includes micro and minor surgical convenience kits, kerrison rongeurs, spinal and general surgical retractors, dural repair kits, synthetic biologics, and a wide range of orthopedic pre-sterilized implants and devices.

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.